Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1655-1659

  Fossa S D ^a   Sternberg, C ^b   Scher, H I ^c   Theodore, C H ^d   Mead, B ^e   Dearnaley, D ^f   Roberts, J T ^g   Skovlund, E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g Northern Centre for Cancer Treatment   (United Kingdom)

Author keywords

Bladder cancer; Chemotherapy; Metastasis

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL PRACTICE; CYSTECTOMY; DRUG FATALITY; DRUG TOXICITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

EID: 0029961445     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.605     Document Type: Article

References (24)

1. AMERICAN CANCER SOCIETY. (1996). Facts and Figures.
2. BOCCARDO F, PACE M, GUARNERI D, CANOBBIO L, CUROTTO A AND MARTORANA G. (1994). Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer, 73, 1932-1936.
3. DIMOPOULOS C, FINN L AND LOGOTHETIS CJ. (1995). Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatin based chemotherapy. J. Urol., 151, 598-601.
4. ENGELAND A, HALDORSEN T, TRETLI S, HAKULINEN T, HÖRTE LG, LOUSTARINEN T, MAGNUS K, SCHOU G, SIGVALDASON H, STORM HH, TULINIUS H AND VAITTINEN P. (1993). Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010: cancer of the urinary bladder. APMIS, 101, 74-77.
5. ENGELAND A, HALDORSEN T, TRETLI S, HAKULINEN T, HÖRTE LG, LUOSTARINEN T, SCHOU G, SIGVALDASON H, STORM HH, TULINIUS H AND VAITTINEN P. (1995). Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis: cancer of the urinary bladder. APMIS. 103, 96-101.
6. FOSSÅ SD, HARLAND SJ, KAYE SB, RAGHAVAN D, RUSSELL JM, PARMAR MKB, USCINSKA BM AND WOOD R FOR THE MRC SUBGROUP IN ADVANCED BLADDER CANCER (1992). Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma. Response rate and pitfalls. Br. J. Urol., 70, 161-168.
7. GABRILOVE JL, JAKUBOWSKI A, SCHER H, STERNBERG C, WONG G, GROUS J, YAGODA A, FAIN K, MOORE MAS, CLARKSON B, OETTGEN HF, ALTON K, WELTE K AND SOUZA L. (1988). Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med., 318, 1414-1422.
8. GELLER NL, STERNBERG CN, PENENBERG D, SCHER H AND YAGODA A. (1991). Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer, 67, 1525-1531.
9. HARKER WG, MEYERS FJ, FREIHA FS, PALMAR JM, SHORTLIFFE LD, HANNIGAN JF, MCWHIRTER KM AND TORTI FM. (1985). Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J. Clin. Oncol., 3, 1463-1470.
10. JEFFERY GM AND MEAD GM. (1992). CMV chemotherapy for advanced transitional cell carcinoma. Br. J. Cancer, 66, 542-546.
11. LOEHRER P, EINHORN LH, ELSON PJM, CRAWFORD D, KUEBLER P, TANNOCK L, RAGHAVAN D, STUART-HARRIS R, SAROSDY MF, LOWE BA, BLUMENSTEIN B AND TRUMP D. (1992). A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J. Clin. Oncol., 10, 1066-1073.
12. LOGOTHETIS CJ, SAMUELS ML, OGDEN S, DEXEUS FH, SWANSON D, JOHNSON DE AND VON ESCHENBACH A. (1985) Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J. Urol., 134, 460-464.
13. LOGOTHETIS CJ, DEXEUS F, FINN L, SELLA A, AMATO RJ, AYALA AG AND KILBOURN RG. (1990). A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J. Clin. Oncol., 8, 1050-1055.
14. MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A. (1981). Reporting results of cancer treatment. Cancer, 47, 207-214.
15. MILLER RS, FREIHA FS, REESE JH, OZEN H AND TORTI FM (1993). Cisplatin, methotrexate, and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J. Urol., 150, 65-69.
16. ROTH BJ. (1995). Preliminary experience with paclitaxel in advanced bladder cancer. Semin. Oncol., 22, 1-5.
17. SENGELØV L, KAMBY C, SCHOU G AND VON DER MAASE H. (1994). Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer, 74, 123-133.
18. STERNBERG CN, YAGODA A, SCHER HI, WATSON RC, HERR HW, MORSE MJ, SOGANI PC, VAUGHAN ED JR, BANDER N, WEISELBERG LR, GELLER N, HOLLANDER PS, LIPPERMAN R, FAIR WR AND WHITMORE WF JR. (1988). M-VAC (methotrexate, vinblatine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the bladder. J. Urol., 139, 461-469.
19. STERNBERG CN, YAGODA A, SCHER HI, WATSON RC, GELLER N, HERR HW, MORSE MJ, SOGANI PC, VAUGHAN ED, BANDER N, WEISELBERG L, ROSADO K, SMART T, SHIOUW-YUN L, PENENBERG D, FAIR WR AND WHITMORE WF (1989). Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer, 64, 2446-2458.
20. STÖCKLE M, MEYENBURG W, WELLEK S, VOGES G, GERTENBACH U, THÜROFF JW, HUBER CH AND HOHENFLLNER R. (1992). Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol., 148, 302-307.
21. STOTER G, SPLINTER TA, CHILD JA, FOSSÅ SD, DENIS L, VAN OOSTEROM AT, DE PAUW M AND SYLVESTER R FOR THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER GENITO-URINARY GROUP. (1987). Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol., 137, 663-667.
22. TANNOCK I, GOSPODAROWICZ M, CONNOLLY J AND JEWETT M. (1989). M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital Experience. J. Urol., 142, 289-292.
23. WAXMAN J, ABEL P, FARAH JN, O'DONOGHUE EPN, MEE D, COBECK R, SIKORA K AND WILLIAMS G. (1989). New combination chemotherapy programme for bladder cancer. Br. J. Urol., 63, 68-71.
24. WITTE R, LOEHRER P, DREICER R, WILLIAMS S AND ELSON P. (1993). Ifosfamide in advanced urothelial carcinoma: an ECOG trial (abstract 707). Proc. Am. Soc. Clin. Oncol., 12, 230.